AMD3100 (Plerixafor) is a CXCR4 antagonist that successfully corrects circulating numbers of neutrophils in neutropenic patients with WHIM syndrome that has been approved for clinical use (McDermott et al., 2014, 2019). Here, CXCR4 is linked to WHIM syndrome.